Gone but not forgotten. Last year, Pfizer stopped manufacturing and recalled products from a Hospira sterile injectables plant in India that the FDA has repeatedly criticized. It recently announced it would close the plant. That didn’t stop the FDA from
read moreAfter pulling off a few large transaction last year, GlaxoSmithKline CEO Emma Walmsley, the only female Big Pharma chief, saw her pay package swell. But that number still lags far behind her male counterparts’ pay—and it’s hardly half what Glaxo’s
read moreAs if BMS didn’t have enough to worry about, what with major investors trying to scuttle its $74 billion Celgene buy, now a new concern has emerged—and it involves one of the six candidates BMS executives have cited as justification
read moreEli Lilly CEO David Ricks, in his second year on the job, snared a larger pay package than those of a few of his Big Pharma peers. And it’s not far shy of the amount his predecessor, John Lechleiter, hauled
read moreA few years ago India’s Alkem Laboratories was in the hot seat with the FDA, having had several plants cited by inspectors. Today it is in the driver’s seat after the agency approved its new valsartan offering to help relieve
read more© 1994 - 2026 B.M. Pharmaceuticals